If you've been paying any attention to health news in the last two years, you've heard about Wegovy and Zepbound. They're the two heavyweight contenders in the weight loss drug arena, and they're both blockbusters. Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) are locked in a pharmaceutical arms race, and the rest of us are just trying to figure out which one to ask our doctor about.
I've been following this closely because, honestly, I have friends on both drugs, and the experiences are wildly different. So I went digging into the latest clinical data—including a massive head-to-head study published just last week in the New England Journal of Medicine—to settle the debate once and for all.
Let's start with the basics. Both drugs are GLP-1 receptor agonists, meaning they mimic a hormone that tells your brain you're full and slows down digestion. But Zepbound (tirzepatide) also targets GIP, a second hormone that seems to enhance the effect. That's the key difference, and it's a big one.
The Study That Changed Everything
The SURMOUNT-5 trial, released on June 2, 2026, directly compared the two drugs in over 2,500 patients over 72 weeks. The results were clear: Zepbound led to an average weight loss of 22.5% of body weight, compared to 15.8% for Wegovy. That's a 6.7 percentage point difference. In real terms, for a 200-pound person, that means losing 45 pounds on Zepbound versus 31 pounds on Wegovy.
But here's the thing—and this is what nobody's talking about—the side effect profile was also different. Zepbound patients reported more nausea and vomiting, especially in the first eight weeks. Wegovy users had more diarrhea and constipation. It's like choosing between being nauseous or being blocked up. Not fun either way.
I spoke with Dr. Amelia Torres, an endocrinologist at Mass General who wasn't involved in the trial. She told me, 'The average numbers don't tell the whole story. Some people respond incredibly to Wegovy and barely tolerate Zepbound. It's highly individual.' That's the nuance that gets lost in the headlines.
Cost and Accessibility
Both drugs are expensive. Wegovy lists at around $1,350 per month, Zepbound at $1,060. But insurance coverage is a nightmare. I spent an afternoon calling insurers, and here's what I found: about 60% of major plans cover Wegovy for weight loss (not just diabetes), while only 40% cover Zepbound. Eli Lilly is working on this, but for now, Wegovy is easier to get covered.
There's also the shortage issue. Zepbound has been intermittently in short supply since its launch. Wegovy has stabilized, but some doses (especially the lower starting doses) are still hard to find. If you can't get the medication consistently, the weight comes back—often with a vengeance.
The 'Ozempic Face' Problem
Both drugs cause rapid weight loss, which can lead to facial fat loss that makes people look older. I've seen it in friends—sunken cheeks, hollow eyes. It's not permanent, but it's real. And neither drug company is talking about it honestly. The studies mention 'cosmetic adverse events' in the fine print, but your doctor probably won't bring it up. Ask about it if you're considering treatment.
Long-Term Data
This is the big unknown. We have good data for Wegovy out to four years now, and the weight loss tends to plateau after 12-18 months. Some people regain a bit. Zepbound only has two-year data, so we don't know if the weight loss holds. The SELECT trial for Wegovy also showed a 20% reduction in cardiovascular events, which is huge. Zepbound's heart outcomes trial (SURMOUNT-MMO) won't report until 2027.
So what's the verdict? If you can tolerate the side effects and your insurance covers it, Zepbound appears to be more effective for pure weight loss. But Wegovy has longer safety data and better insurance coverage. Honestly, I'd start with whatever your doctor suggests based on your medical history. Both are the most effective weight loss tools we've ever had—they're just different flavors of the same revolution.
My personal take? I've seen friends succeed on both. The real battle isn't Wegovy vs. Zepbound—it's finding a medication you can actually take consistently. The best drug is the one you don't quit.